Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Procedure: Surgical Resection; Drug: Adjuvant Atezolizumab-Bevacizumab Therapy Sponsors: National Cancer Centre, Singapore; Singapore General Hospital; National University Hospital, Singapore; Changi General Hospital; Sengkang General Hospital; Tan Tock Seng Hospital; Singapore Clinical Research Institute; Genome Institute of Singapore; I nstitute of Molecular and Cell Biology of Singapore; Cancer Science Institute of Singapore; Duke-NUS Graduate Medical School; Singapore Phenome Centre; Nanyang Technological University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Biology | Cancer & Oncology | Carcinoma | Cytology | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Molecular Biology | Research | Singapore Health